Aggregation of Human Blood Platelets by Remnant Like Lipoprotein Particles of Plasma Chylomicrons and Very Low Density Lipoproteins

Summary

Remnant like lipoprotein particles (RLP) of partially catabolised human plasma chylomicrons (CM) and very low density lipoproteins (VLDL) were separated from CM and VLDL using two monoclonal antibodies, anti apo B-100 (JI-H) and anti apo A-I (H-12) coupled to Sepharose 4B gel to form an immunoaffinity column. Lipoproteins containing apo B-100 or apo E, including VLDL and LDL adsorb to (JI-H)-gel, while CM and HDL with apo A-I adsorb to (H-12)-gel. The unbound fraction (RLP) is rich in apo B-48, apo E and apo E rich apo B-100 which has not been recognized by JI-H. The RLP fraction with a total triglyceride of 12.35 ± 6.22 mg/ml; total cholesterol, 0.32 ± 0.08 mg/ml and total protein, 0.72 ± 0.12 mg/ml (mean ± S.E.M, n = 9) was added to blood from healthy persons at 2.5-200 |xl/ml and agitated gently at 37° C for 40 s. Platelet aggregation was assessed by measuring the loss of single platelets. At 2.5-10 μl, RLP induced platelet aggegation increased with the dose of RLP, but decreased at 25-200 julL Scanning electron microscopy revealed that within 20 s of agitation in the presence of RLP, activated platelets had appeared on the red cell membrane and within 40 s of agitation, platelet aggregates had formed on the red cells. The platelet responses were unaffected by aspirin (10 or 20 μg/ml) but were inhibited by cilostazol, a phosphodiesterase type III inhibitor (0.4 to 1.6 μg/ml). It is likely that the platelet effect of RLP is a consequence of RLP dependent red cell-platelet interaction. This is the first report of platelet aggregation induced by RLP without an added platelet agonist.

• References

• 1 Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473-480
• 2 Philips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993; 88: 2762-2770
• 3 Havel RJ. Postprandial Hyperlipidaemia and remnant lipoproteins. Curr Opinion Lipidol 1994; 5: 102-109
• 4 Havel RJ, Rapaport E. Management of primary hyperlipidaemia. N Engl J Med 1995; 332: 1491-1498
• 5 Readon MF, Nestel PJ, Graig IH, Harper RW. Lipoprotein predictors of severity of coronary artery disease in men and women. Circulation 1985; 71: 881-888
• 6 Bom GVR. Haemorheological influences on platelet thrombogenesis. Clin Haemorheol 1985; 5: 891-897
• 7 Surya I, Akkerman JWN. The influence of lipoproteins on blood platelets. Am Heart J 1993; 125: 272-275
• 8 Carvalho CA, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Eng J Med 1974; 290: 434-438
• 9 Editorial. Lipids, platelets and atherosclerosis. Lancet 1980; 1: 464-465
• 10 Corash L, Schaefer E, Poindexter E, Anderson J. Platelet function and survival in familial hypercholesterolaemia. Circulation 1976; 54: II-117
• 11 Knӧfler R, Nakano T, Nakajima K, Takada Y, Takada A. Remnant-like lipoproteins stimulate whole blood platelet aggregation in vitro. Thromb Res 1995; 78: 161-171
• 12 Orth M, Luley C, Wieland H. Effects of VLDL and chylomicron remnants on platelet aggregability. Thromb Res 1995; 79: 297-305
• 13 Sekihara T, Nakano T, Nakajima K. High postprandial plasma remnant-like particles-cholesterol in patients with coronary artery disease on chronic maintenance haemodialysis (in English). Jpn J Nephrol 1996; 38: 220-228
• 14 Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apo E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 1992; 33: 369-380
• 15 Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ. Cholesterol in remnant like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clinica Chemica Acta 1993; 223: 53-71
• 16 Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Murase T. A new approach for detection of type III hyperlipoproteinemia by RLP-cholesterol assay. J Atheroscl Thromb 1994; 1: 30-36
• 17 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193: 265-275
• 18 Thompson WJ. Cyclic nucleotide phosphodiesterase: pharmacology, biochemistry and function. Pharmacol Ther 1991; 51: 13-33
• 19 Okuda Y, Kimura Y, Yamashita K. Cilostazol. Cardiovasc Drug Rev 1993; 11: 451-465
• 20 Fox SC, Burgess-Wilson M, Heptinstall S, Mitchell JR. Platelet aggregation in whole blood determined using the Ultra Flo 100 platelet counter. Thromb Haemost 1982; 48: 327-329
• 21 Saniabadi AR, Lowe G, Barbenel JC, Forbes CD. Effect of dipyridamole on spontaneous platelet aggregation in whole blood decreases with the time after venepuncture: evidence for the role of ADP. Thromb Haemost 1987; 58: 744-748
• 22 Moncada S, Vane JR. Pharmacological and endogenous roles of prostaglandin endoperoxides, thromboxane A₂and prostacyclin. Pharmacol Rev 1988; 30: 293-331
• 23 Patrono C. Aspirin and human platelets: from clinical trials to the acetylation of cyclo-oxygenase and back. Trends Pharmacol Sci 1989; 10: 453-458
• 24 Reinhart WH, Chien S. Red cell rheology in stomatocyte-echinocyte transformation: roles of cell geometry and cell shape. Blood 1986; 67: 1110-1118
• 25 Umekawa H, Tanaka T, Kimura Y, Hidaka H. Purification of cyclic adenosine monophosphate diesterase from human platelets using new inhibitors Sepharose chromatography. Biochem Pharmacol 1984; 33: 3339-3344
• 26 Tani T, Sakurai K, Kimura Y, Ishikawa T, Hidaka H. Pharmacological manipulation of tissue cyclic AMP by inhibitors: effect of phosphodiesterase inhibitors on the function of platelets and vascular endothelial cells. Adv Second Messenger Phosphoprot Res 1992; 25: 215-228
• 27 Saniabadi AR, Lowe G, Barbenel JC, Forbes CD. Further studies on the role of red blood cells in spontaneous platelet aggregation. Thromb Res 1985; 38: 225-232
• 28 Koller E, Koller F, Doleschel W. Specific binding sites on human blood platelets for plasma lipoproteins. Hoppe-Seylers Z Physiol Chem 1982; 363: 395-405
• 29 Hellem AJ. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 1960; 12 (Suppl. 51) 001-117
• 30 Gaader A, Jonsen J, Laland S, Hellem A. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532
• 31 Saniabadi AR, Lowe G, Barbenel JC, Forbes CD. A comparison of spontaneous platelet aggregation in whole blood with platelet rich plasma: additional evidence for the role of ADP. Thromb Haemost 1984; 51: 115-118
• 32 Born GVR. Fluid mechanical and biochemical interactions in haemostasis. Br Med Bull 1977; 33: 193-197
• 33 Morganroth J, Levy RI, Fredrickson DS. The biochemical, clinical and genetic features of type III hyperlipoproteinaemia. Ann Intern Med 1975; 82: 158-174
• 34 Kane JP, Chen GC, Hamilton RL, Hardman DA, Malloy MJ, Havel RJ. Remnants of lipoproteins of intestinal and hepatic origin in familial dysbetalipoproteinaemia. Arteriosclerosis 1983; 3: 47-56